Stojanović Novković, S.; Šelemetjev, S.; Krajnović, M.; Božović, A.; Kožik, B.; Prosenc Zmrzljak, U.; Išić Denčić, T.
Implication of p16 Promoter Methylation, the BRAFV600E Mutation, and ETS1 Expression Determination on Papillary Thyroid Carcinoma Prognosis and High-Risk Patients’ Selection. Biomedicines 2025, 13, 1583.
https://doi.org/10.3390/biomedicines13071583
AMA Style
Stojanović Novković S, Šelemetjev S, Krajnović M, Božović A, Kožik B, Prosenc Zmrzljak U, Išić Denčić T.
Implication of p16 Promoter Methylation, the BRAFV600E Mutation, and ETS1 Expression Determination on Papillary Thyroid Carcinoma Prognosis and High-Risk Patients’ Selection. Biomedicines. 2025; 13(7):1583.
https://doi.org/10.3390/biomedicines13071583
Chicago/Turabian Style
Stojanović Novković, Stefana, Sonja Šelemetjev, Milena Krajnović, Ana Božović, Bojana Kožik, Uršula Prosenc Zmrzljak, and Tijana Išić Denčić.
2025. "Implication of p16 Promoter Methylation, the BRAFV600E Mutation, and ETS1 Expression Determination on Papillary Thyroid Carcinoma Prognosis and High-Risk Patients’ Selection" Biomedicines 13, no. 7: 1583.
https://doi.org/10.3390/biomedicines13071583
APA Style
Stojanović Novković, S., Šelemetjev, S., Krajnović, M., Božović, A., Kožik, B., Prosenc Zmrzljak, U., & Išić Denčić, T.
(2025). Implication of p16 Promoter Methylation, the BRAFV600E Mutation, and ETS1 Expression Determination on Papillary Thyroid Carcinoma Prognosis and High-Risk Patients’ Selection. Biomedicines, 13(7), 1583.
https://doi.org/10.3390/biomedicines13071583
